Danaher Corporation (DHR) stock: key figures, P/E, revenue and dividend
Health Care · Life Sciences Tools & Services · United States · ISIN US2358511028
Danaher Corporation financials
| Fiscal year | 2025 |
|---|---|
| Revenue | 24.57 bn USD |
| Gross profit | 14.52 bn USD |
| Operating income | 4.69 bn USD |
| EBIT | 4.48 bn USD |
| Net income | 3.61 bn USD |
| Diluted EPS – continuing operations | 5.05 USD |
Full history since 1985, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Danaher Corporation
Danaher Corporation designs, manufactures, and markets professional, medical, research, and industrial products and services in the United States, China, and internationally. The company operates through Biotechnology, Life Sciences, and Diagnostics segments. The Biotechnology segment provides technologies, consumables, services, and solutions that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, and aseptic fill finish; single-use hardware, consumables, and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services for diagnostic and assay development; and healthcare filtration solutions. The Life Sciences segment provides mass spectrometers; bioanalytical measurement systems; flow cytometry, genomics, lab automation, centrifugation, liquid handling automation instruments, antibodies and reagents, and particle counting and characterization; genome sample preparation; microscopes; protein consumables; filtration products; and genomic medicines, such as custom nucleic acid products, and plasmid DNA, RNA, and proteins under the ABCAM, ALDEVRON, BECKMAN COULTER, GENEDATA, IDT, LEICA MICROSYSTEMS, MOLECULAR DEVICES, PALL, PHENOMENEX, and SCIEX brands. The Diagnostics segment offers clinical instruments, consumables, software, and services that hospitals, physicians' offices, reference laboratories and other critical care settings use to diagnose disease and make treatment decisions. The company was formerly known as Diversified Mortgage Investors, Inc. and changed its name to Danaher Corporation in 1984. Danaher Corporation was incorporated in 1969 and is headquartered in Washington, the District Of Columbia.
More stocks
- DBS Group Holdings Ltd (D05.SI)
- Seagate Technology (STX)
- NextEra Energy (NEE)
- China Shenhua Energy Co (601088.SS)
- Recruit Holdings Co Ltd (6098.T)
- Advantest Corp (6857.T)
- Anheuser-Busch Inbev SA (ABI.BR)
- Eaton Corporation (ETN)
- Hitachi Ltd (6501.T)
- AT&T (T)
- Anheuser Busch Inbev NV ADR (BUD)
- TJX Companies (TJX)
Not investment advice. All data without warranty, price as of 14.10.2026. Details in the risk notice.